NEWS

Contact:
Paul Oestreicher, Ph.D.
Oestreicher Communications, LLC
917-536-3523

FOR IMMEDIATE RELEASE
12 February 2009

American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruaño to College of Fellows

Dr. Ruaño's Pioneering Contributions to Personalized Medicine Cited for Honor

HARTFORD, CT and Washington, DC – Gualberto Ruaño, M.D., Ph.D., was inducted into the American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows today at a ceremony in Washington, DC at the National Academy of Sciences. Recipients of this honor are chosen for exceptional leadership and achievements in medical and biological engineering. Dr. Ruaño is President and Chief Executive Officer of Genomas Inc., Director of Genetics Research at Hartford Hospital, and Adjunct Professor in the medical faculties at George Washington University and at the University of Puerto Rico.

"Dr. Ruaño is among the most imaginative and distinguished innovators and entrepreneurs in personalized medicine," said Jennifer Ayers, MPA, Executive Director, AIMBE. "AIMBE is proud to count him among the top tier of biomedical engineers elected to the College of Fellows." At AIMBE, the College of Fellows leads the way in technological advancement, advocating for public policies facilitating progress in medical and biological research and development to benefit the public. As the array of companies and entire industries based on biotechnology and bioengineering has expanded rapidly, AIMBE Fellows have assumed leading roles in both their R&D and management functions, driving the movement of new medical technologies to patient care. Fellows hold numerous patents that have helped make medical and biological engineering a major economic force in the U.S., generating $200 billion in revenue annually and supporting thousands of high-paying jobs.

"I am very honored by this appointment to the AIMBE College of Fellows. Based on my experience at Genomas and Hartford Hospital, advancing DNA-Guided Medicine to clinical practice requires integration of molecular technologies, medical decision algorithms, and physician user interfaces. Such synthesis indeed is a feat of biomedical engineering," said Dr. Ruaño. "I look forward to working with AIMBE and its fellows in this quest to bring personalized medicine to healthcare."

In his 25-year scientific and medical career, Dr. Ruaño has developed systems for DNA-guided medicine based on genomics, nanoscience, and clinical informatics. At Genomas, he has pioneered physiotypes based on multi-gene markers and bioclinical algorithms for the prediction of human drug response and DNA-guided medicine in patient care. Genomas (since 2003) is the clinical embodiment of successful serial entrepreneurship by Dr. Ruaño, which spanned BIOS Labs (1992-96) in research technologies and Genaissance (1997-2002) in pharmaceutical R&D.

(more)

Among his many contributions, Dr. Ruaño invented the Coupled Amplification and Sequencing system incorporated in TRUGENE™, the first FDA-approved pharmacogenomic diagnostic, now marketed worldwide by Siemens Healthcare. He also was pivotal in the advancement of gene haplotypes for clinical trials and target validation in pharmaceutical development. Dr. Ruaño is a founding Director of the Personalized Medicine Coalition in Washington, DC, senior editor of the journal *Personalized Medicine* (London), and a Fellow of the National Academy of Clinical Biochemistry. He obtained M.D. and Ph.D. degrees from Yale University. He obtained his B.A. degree from Johns Hopkins University, where he was elected to Phi Betta Kappa.

Elliot Joseph, President, Hartford Hospital, commented: "Dr. Ruaño's election to the AIMBE College of Fellows is a tribute to his contributions not only to the development of new biomedical technologies but also to the enhancement of patient care. In his five years at Hartford Hospital, he has been instrumental in advancing our institution to become one of the key national centers of excellence in the clinical practice of personalized medicine."

ABOUT THE AMERICAN INSTITUTE FOR MEDICAL AND BIOLOGICAL ENGINEERING (AIMBE)

Founded in 1991, AIMBE's mission includes raising awareness of medical and biological engineering and of achievements in the field, building relationships with government and professional groups, improving cooperation within the field of medical and biological engineering and promoting the national interest in science, engineering, and education. The contributions of AIMBE fellows have had a major impact in biomedical devices and processes, treatment of diseases, and public policy related to all aspects of health. The College of Fellows includes the heads of engineering and medical schools at major universities. Fellows are members of the National Academy of Engineering, the Institute of Medicine and the National Academy of Sciences. Fellows hold the National Medal of Science and the National Medal of Technology. Please visit *www.aimbe.org* for more information.

ABOUT HARTFORD HOSPITAL

Hartford Hospital is an 867-bed regional referral center that provides high-quality care in all clinical disciplines. Among its divisions is The Institute of Living, a 114-bed mental health facility with a national and international reputation of excellence. Jefferson House, a 104-bed long-term care facility, is also a special division of Hartford Hospital. The Hospital major centers of clinical excellence include cardiology, oncology, emergency services and trauma, mental health, women's health, orthopedics, bloodless surgery and advanced organ transplantation. Hartford Hospital owns and operates the state's only air ambulance system, LifeStar. Hartford Hospital employs more than 6,600 full-time or part-time employees and a medical staff of more than 970 active staff physicians. Hartford Hospital, founded in 1854, is one of the largest teaching hospitals and tertiary care centers in New England with the region's busiest surgery practice, and has been training physicians for nearly 130 years.

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType™ Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes, and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit *www.genomas.net* for more information.

ABOUT PHYZIOTYPE SYSTEMS FOR DNA-GUIDED MEDICINE

PhyzioType™ Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. They are being developed for DNA-Guided Medicine in the prescription of cardiovascular, psychotropic and diabetes drugs and in preventive cardiology. The research leading to the PhyzioType Systems has been published in the renowned journals *Annals of Biomedical Engineering, Biomedical Engineering Handbook, Molecular Psychiatry, Muscle & Nerve, Pharmacogenomics* and *Clinica Chimica Acta*. To date, Genomas has secured $3.3 million from NIH Small Business Innovation Research (SBIR) and filed 7 patent applications for PhyzioType System product development.

###